Abstract | The 826 G protein-coupled receptors (GPCRs) in the human proteome regulate key physiological processes and thus have long been attractive drug targets. With the crystal structures of more than 50 different human GPCRs determined over the past decade, an initial platform for structure-based rational design has been established for drugs that target GPCRs, which is currently being augmented with cryo-electron microscopy (cryo-EM) structures of higher-order GPCR complexes. Nuclear magnetic resonance (NMR) spectroscopy in solution is one of the key approaches for expanding this platform with dynamic features, which can be accessed at physiological temperature and with minimal modification of the wild-type GPCR covalent structures. Here, we review strategies for the use of advanced biochemistry and NMR techniques with GPCRs, survey projects in which crystal or cryo-EM structures have been complemented with NMR investigations and discuss the impact of this integrative approach on GPCR biology and drug discovery.
More than 30% of all drugs approved by the US Food and Drug Administration (FDA) target G protein-coupled receptors (GPCRs) [1] [2] [3] , and these drugs are utilized in a wide range of therapeutic areas, including inflammation and diseases of the central nervous system as well as the cardiovascular, respiratory and gastrointestinal systems 2, 4 . Currently, more than 300 agents are in clinical trials, of which around 60 target novel GPCRs for which no drug has as yet been approved 2 . The novel GPCR targets also include orphan GPCRs, for which endogenous ligands have not yet been discovered 2 . Overall, the drugs approved so far target only 27% of the human non-olfactory GPCRs 2 , indicating that much excitement still lies ahead.
Identifying new GPCR drugs will need additional detailed knowledge of GPCR biology, especially knowledge from structural biology, given the complex structure-function relationships involved in GPCR signalling. Along this line, recent reviews on GPCRs have covered studies with antibodies 5 and nanobodies 6 , allosteric modulation [7] [8] [9] [10] , biased signalling [11] [12] [13] [14] [15] , methods in GPCR structural biology [16] [17] [18] [19] , GPCR crystal structures [20] [21] [22] [23] [24] [25] [26] [27] and drug development 2, 4, 28, 29 , with some reviews addressing specific GPCR families 30, 31 . Complementing the substantial number of GPCR crystal structures that have become available in the past decade, as well as the recent demonstrations of the potential for cryo-electron microscopy (cryo-EM) to provide information on higherorder GPCR complexes [32] [33] [34] [35] [36] , dynamic studies of GPCRs are important for providing new insights into GPCR biology that can assist drug discovery. In this respect, nuclear magnetic resonance (NMR) spectroscopy in solution is a key tool for analysing function-related conformational equilibria in GPCRs as they relate to allosteric coupling, variable efficacy and biased signalling of GPCR ligands, which are of particular interest for their potential as drugs. Furthermore, NMR spectroscopy is also a useful tool for fragment-based lead discovery with GPCR targets.
In this Review, we first overview the structural biology of GPCRs based on knowledge from X-ray crystallography, cryo-EM and solution NMR and then focus on the application of solution NMR to enhance the understanding of GPCR biology relevant to drug discovery, as well as in fragment-based lead discovery. Solid-state NMR studies can also be valuable in the study of GPCR and other membrane protein structures, but have been reviewed elsewhere [37] [38] [39] [40] [41] [42] [43] and are not covered here.
Structural biology of GPCRs
Human GPCR biology. GPCRs are one of the largest membrane protein families in eukaryotes. There are 826 GPCRs in the human proteome, which are classified into five main families based on sequence homology and phylogenetic analyses: rhodopsin family (class A), 
Conformational equilibria
Solution NMR studies established that G protein-coupled receptors in near-physiological environments exist in multiple, locally different conformers that are simultaneously populated in function-related equilibria. It has been shown that the relative populations of these conformers are related to the efficacies and the bias of bound drugs.
Efficacy
The extent to which a G protein-coupled receptor (GPCR) ligand changes the receptor signalling intensity relative to its basal level. The efficacy is a key determinant of the therapeutic properties of a GPCR-targeting drug.
Motif
A polypeptide segment of two or several amino acids that are highly conserved among G protein-coupled receptors of a given class. Motifs have been identified as key components of activation centres, which are clusters of closely spaced amino acids in the 3D structure.
secretin family (class B), glutamate family (class C), frizzled family (class F) and adhesion family 22, 44 . GPCRs function as receptors for various neurotransmitters, hormones, cytokines (chemokines), metabolites, tastants and odorants. In addition to being a key class of drug targets, GPCRs are frequent 'off-targets' of drugs that target other proteins, which can result in unanticipated side effects, and mutations of GPCRs have been linked to dozens of monogenic diseases 22, 29 . Activated GPCRs induce signal transduction mediated by G proteins, GPCR kinases (GRKs) and arrestins 12, 16, 22, 24, 45 (FIG. 1a) . Upon G protein activation, the Gα subunit dissociates from the Gβγ subunits and modulates the production of second messengers such as cAMP. Gβγ modulates downstream signalling networks, including ion channels and phospholipases. In addition, the activated GPCRs may be phosphorylated by GRKs, and the phosphorylated GPCRs stimulate G proteinindependent signal transduction mediated by arrestins (FIG. 1a) , such as receptor internalization and activation of kinase signalling networks.
Different GPCR ligands can modulate signalling through G protein and arrestin pathways differently, and the ligands that preferentially modulate one of the signalling pathways are referred to as 'biased ligands' [11] [12] [13] [14] [15] [45] [46] [47] [48] [49] ( FIG. 1b) . Differences in biased signalling critically affect the therapeutic properties of GPCR ligands. Drugs can produce side effects mediated through the activation of unwanted signalling pathways by the targeted GPCR, and so it is of keen interest to minimize such side effects by designing biased ligands that selectively activate the signalling pathway required to produce the desired therapeutic response 11, 12, 50, 51 . For example, G proteinbiased agonists of the μ-opioid receptor (MOR) increase analgesia and reduce the on-target adverse effects compared with morphine [52] [53] [54] [55] [56] [57] , and several novel biased ligands are under evaluation in clinical trials 12 
(FIG. 1c).
This work is of great socioeconomic interest owing to the crisis caused by the misuse of prescription opiates in the United States 58 . In addition to the bias between the G protein and arrestin pathways, many other types of bias have been proposed, including those between different G protein subtypes 59 . GPCRs exhibit variable basal activities in the absence of bound ligands, and each ligand for a given GPCR has a characteristic level of ability to activate or deactivate its target, which is commonly referred to as its efficacy. According to their efficacies, GPCR ligands are classified as full agonists, partial agonists, antagonists and inverse agonists 22, 60 (FIG. 1d ). These differences in efficacy affect the therapeutic properties of the GPCR ligands, and partial agonists can offer clinical advantages over full agonists and antagonists 11, [61] [62] [63] [64] (FIG. 1e) .
Most descriptions of biased agonism were initially based on studies using recombinant cell systems 50 . Although consistent and robust responses of different signalling pathways can thus be obtained 50 , many factors can confound the interpretation of these assays, including off-target effects, cell backgrounds, receptor and effector expression levels, and the kinetic properties of agonists 11, 50, 65 . Thus, the integration of studies using recombinant cell systems with structural biology to detect direct effects on the receptor conformation is important in studying biased agonism.
X-ray crystal and cryo-EM structures of human GPCRs.
Since the first crystal structure of bovine rhodopsin published in 2000 (REF.
66
) and the first crystal structure of a human GPCR, β 2 -adrenergic receptor (β 2 AR), published in 2007 (REFS 67, 68 ), the number of GPCR crystal structures has rapidly increased, and structures of more than 50 different GPCRs and over 250 of their complexes with different ligands are presently available in the Protein Data Bank, as documented in the GPCRdb 69 (FIG. 2) . This includes structures of class A, class B, class C and class F receptors 69 . Cryo-EM structures of GPCRs in complexes with partner proteins are also appearing at an increasingly rapid pace. Examples include tertiary complexes of receptors with G proteins and agonists of the glucagon-like peptide 1 receptor (GLP1R) 35 , the calcitonin receptor 36 , the A 1 adenosine receptor 70 , MOR 71 , the serotonin 5HT 1B receptor 33 and rhodopsin 34 . Crystal structures have revealed the GPCR 3D architectures, locations of bound ligands and atomic details of receptor-ligand interactions. All class A GPCRs share a structural topology characterized by seven transmembrane helices (TMI to TMVII) linked by three intracellular loops (ICLs) and three extracellular loops (ECLs). A canonical 'orthosteric' ligand-binding pocket facing the extracellular surface is formed by residues of transmembrane helices and ECLs 22, 72 (FIG. 2) . Crystal structures have also identified ligand-binding sites in transmembrane regions outside of the orthosteric pocket of class A 73 and class B 74 receptors, which relate to allosteric modulation of effects from orthosteric ligand binding (FIG. 2) . In GPCR crystal structures determined at resolutions of 2.5 Å or higher, small molecules and ions have been observed, including bound sodium 75, 76 , networks of crystallographic water molecules 75 , lipids and cholesterol 77 , providing a structural basis for rationalizing the regulation of GPCRs by allosteric modulators. Knowledge of mechanisms underlying allosteric modulators can in turn provide novel insights into signal transduction through GPCRs. Exogenous allosteric modulators may be useful for the development of GPCR subtype-specific drugs, where different subtypes may have nearly identical orthosteric sites 78 . The crystal structures of β 2 AR indicated the following structural mechanism for class A GPCR activation [78] [79] [80] [81] (FIG. 3) . Full agonists induce a rearrangement of the interactions between transmembrane helices in the central part of the GPCR structure, that is, an inward shift of TMV at P211 5.50 , an axial shift of TMIII at I121 3.40 and an outward shift of TMVI starting at F282 6.44 (the four-digit superscripts indicate the Ballesteros-Weinstein nomenclature 82 for amino acid residues in GPCRs, where the first number indicates the helix in which the residue is located). These three residues are referred to as the P/I/F motif. The rearrangement of the transmembrane helices induces a large outward movement of the cytoplasmic half of TMVI and thus increases the distance between TMIII and TMVI in the cytoplasmic region and disrupts a salt bridge in an ionic lock, which accompanies the repositioning of the side chain of Y326 7.53 in a second highly conserved motif consisting of residues NPxxY. The residues that exhibit conformational changes upon activation of β 2 AR are highly conserved among the class A GPCRs 81, 83, 84 , and when comparing antagonistbound states and ternary complexes with agonists and G protein mimetics, similar conformational differences were observed for other class A GPCRs. Similar conformational changes upon activation (FIG. 3a) thus seem to be characteristic among the class A GPCRs.
In a crystal structure of the ternary complex of β 2 AR with a full agonist and a G protein 85 , a cytoplasmic cavity is formed by the outward shift of the cytoplasmic half of TMV and TMVI and the distortion of TMVII, compared with their conformations in the inverse agonist-bound form 68 ; the carboxy-terminal helix of the G protein is then inserted into the cytoplasmic cavity. Similar cytoplasmic cavity formation was observed for the crystal structures of other GPCRs in tertiary complexes with a full agonist and a G protein mimetic 86 , as well as for cryo-EM structures of GPCRs in tertiary complexes with an agonist and a G protein 33, 34, 70, 71 . GPCR crystal structures have been extensively utilized for structure-based drug design, and there are more than 30 reports on the in silico screening of GPCR ligands, some of which resulted in the identification of GPCR ligands with novel chemical scaffolds 22, 87 . However, information on GPCR features that are of special interest to drug discovery, such as basal activity, biased signalling, partial agonism and allosteric modulation by ions and small molecules, can only be partially derived from crystallography data. These limitations arise in large part from the well-established practice of making modifications to the wild-type GPCR covalent structure to facilitate crystallization, such as truncation of flexible domains and chain ends, introduction of soluble fusion proteins into the loops or at the receptor amino terminus 88, 89 and systematic replacement of endogenous amino acids to increase thermostability [90] [91] [92] . Alternatively, crystallization has also been facilitated by the formation of stable non-covalent complexes with a partner protein, such as an engineered G protein 93 , antibody 94 or nanobody 6, 81 , but this can also affect functionally relevant conformational equilibria.
An illustration of the limitations is provided by the β 1 -adrenergic receptor (β 1 AR), which was thermostabilized by modifications that also trap the receptor in an inactive state. The crystal structures then showed nearly identical conformations for complexes with antagonists, a partial agonist, a full agonist and a biased agonist 92, 95 . GPCR crystallography also depends on the selection of the orthosterically bound ligand. All small-molecule ligands used so far appear to have similar chemical properties and high binding affinity (K i ≤10 nM) 96 and thus probably provide information on only a fraction of the drug scaffolds that can potentially be recognized by GPCRs. Crystal structure determination is particularly challenging for GPCRs that bind endogenous or synthetic peptides, such that only a few crystal structures 6.44 and the bound ligands are depicted by cyan or orange sticks, as detailed in the figure. The antagonist and full agonist complexes differ by a rearrangement of the transmembrane helices and the P/I/F activation motif of P211 5.50 , I121
3.40 and F282 6.44 . The rearrangement at the P/I/F motif induces conformational changes near the cytoplasmic region that is involved in G protein binding. The environments around M82 2.53 , M215
5.54 and C265 6.27 have been shown to be sensitive to the above-described conformational changes upon activation. b | Schematic model of plasticity in β 2 AR, which rationalizes the wide range of different exchange rates in part a. Vertical arrows indicate the equilibria between inactive and active-like conformations at the cytoplasmic surface, as observed with NMR probes at C265. Horizontal arrows correspond to equilibria in the local region around M82 (PIFoff 1 ↔PIFoff 2 ) and in the P/I/F motif (PIFoff 2 ↔PIFon), as observed with probes at M82 (the states PIFoff 1 have been determined so far for GPCRs complexed with peptides 23 ; these include endothelin 97 , neurotensin 98 and the neuropeptide Y 1 receptor 99 . As peptide therapeutics are promising 2 , especially for class B GPCRs, other techniques such as NMR may be valuable in providing more comprehensive structural information on GPCR-peptide drug systems.
In summary, the success of GPCR crystallography has also revealed the need to complement crystal structures with data collected using different techniques in milieus that are closer to physiological conditions than the crystalline state and liquid nitrogen temperature, and solution NMR is particularly promising in this respect.
NMR data and GPCR functions. NMR methods provide information about the dynamics of proteins over a wide range of frequencies in aqueous solutions at nearphysiological temperature [100] [101] [102] . NMR studies thus revealed that global and local conformational fluctuations of protein structures are closely related to their functions, such as enzymatic activities 103, 104 or molecular recognition 105 , especially for membrane proteins [106] [107] [108] [109] . Although NMR studies of GPCRs are challenging, observations of the NMR signals of various GPCRs have been accomplished through recent methodological advances, including ultra-high-field NMR instruments, improved cryogenic probes, transverse relaxation-optimized spectroscopy (TROSY) 110, 111 and refined methods for labelling with stable isotopes and other NMR probes
.
NMR studies, along with various other spectroscopic studies, have revealed that GPCRs exist in functionrelated equilibria between multiple locally different conformations that are simultaneously populated. These function-related equilibria are typically abolished by the modifications used for crystallography studies described above. NMR studies thus provide information that is complementary to data from X-ray crystallography and cryo-EM studies, which should be considered in functional interpretations of GPCR crystal structures. NMR can also be used for serial analyses of the conformations of GPCRs bound to various ligands with different efficacies and extent of biased signalling [112] [113] [114] [115] , whereas the determination of the crystal structures in a wider range of ligand-bound states is not straightforward for GPCRs 22 . TABLE 1 summarizes recent NMR studies of conformational equilibria in GPCRs that relate to partial agonism and biased signalling [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] , which could facilitate the design of new compounds that can modulate GPCR signalling.
In addition to observing GPCRs and their interactions with drugs and partner proteins, NMR has been used to directly observe GPCR ligands in both their unbound and receptor-bound conformations. This enables the determination of structures of GPCR ligands and measurement of their conformational dynamics while bound to the receptor and, in principle, their drug pharmacokinetics. Some examples from a very large array of literature data on this topic include the determination of the structure of the agonist dynorphin bound to the κ-opioid receptor 132 , the cytokine interleukin-8 and its interactions with the chemokine receptor CXCR1 (REFS
133,134
), ligands of the free fatty acid receptor 135 and peptide agonists of the bradykinin receptors 136 . Importantly, NMR can be used to monitor the relatively weak interactions of lowmolecular-mass compounds with GPCRs and therefore can support fragment-based lead discovery approaches. Finally, NMR has been used to study the structure and dynamics of GPCR partner proteins, including G proteins and arrestins, and their interactions with GPCRs and nucleotides [137] [138] [139] . Thus, in addition to information from NMR observation of GPCRs, NMR can provide a comprehensive view of a wide range of molecules that interact with GPCRs and modulate GPCR signalling.
NMR studies of human GPCRs NMR studies on the dynamics of GPCRs related to their functions have so far typically been performed in the following manner. First, labelled GPCRs are prepared using fluorine and/or stable-isotope labelling methods (BOX 1) and reconstituted in detergent micelles or lipid nanodiscs , and the solvent accessibility of the observed atoms can be assessed by the addition of paramagnetic probes to the solvent 112, 144 . Exchange rates and species populations in conformational equilibria can be determined by lineshape analysis 145 , CPMG 122 , saturation transfer 119, 120, 122 and exchange spectroscopy 120 , including perturbation of an equilibrium by changing the temperature. The functional relevance of the observed conformational changes can then be explored by investigations of the relationships between the NMR spectra and the signalling activities of the GPCRs.
In the following sections, results obtained using these approaches with different individual GPCRs are described, with most examples from GPCRs in class A, which is the largest phylogenetic class of GPCRs 79 . Among almost 700 class A GPCRs, 296 are non-olfactory GPCRs that function as receptors of various hormones and neuro transmitters and are the most commonly exploited GPCRs for pharmacological interventions 22 . NMR studies of class A GPCRs have provided insights into the mechanisms enabling partial agonism and biased signalling, with β 2 AR as the representative of class A GPCRs with the most extensive set of experimental data. Exploratory NMR measurements with other class A GPCRs have clearly indicated that all the information gathered for β 2 AR is not readily applicable for other GPCRs, and increasing interest has recently been focused on structural and functional studies of other class A GPCRs. β 2 -Adrenergic receptor. The conformational dynamics of β 2 AR, a class A GPCR stimulated by adrenaline and various bronchodilators, has been extensively studied by multiple groups (TABLE 1) . NMR signals have been observed for CF 3 groups of 2,2,2-trifluoroethanethiol (TET) 112, 120 ,
Box 1 | Preparation of native-like human GPCRs for solution NMR

Expression systems
Protein production for most published G protein-coupled receptor (GPCR) NMR studies has been carried out using insect cell-baculovirus expression systems (BVES), which are also routinely used for protein production in GPCR crystallography. More recently, mammalian cell cultures have been employed for the expression of GPCRs with large extracellular domains, as typically found in class B and class F GPCRs 229, 230 , which also retain human-like glycosylation and other post-translational modifications. Several human GPCRs have also been recombinantly expressed in yeast, particularly in Pichia pastoris [231] [232] [233] , including the histamine H 1 receptor 234 and the A 2A adenosine receptor (A 2A AR) 235 . A survey of expression systems used for the preparation of GPCR NMR samples is included in TABLE 1.
Labelling by post-translational chemical modification
Many GPCR NMR studies to date have introduced NMR probes by chemical modification of amino acid side chains during or after protein production. This strategy benefits from the comparatively high expression yields for wild-type-like GPCRs, as NMR probes are incorporated in a post-translational step during protein purification at specific locations in the receptor through chemical conjugation to reactive -SH or -NH 3 groups of amino acid side chains. Two common extrinsic GPCR NMR probes are 19 F groups chemically conjugated with cysteines and 13 CH 3 groups introduced by the reductive methylation of lysines. The use of trifluoromethyl probes in integral membrane proteins was pioneered by Khorana for NMR studies of bovine rhodopsin 236 and more recently applied to studies of the β 2 -adrenergic receptor (β 2 AR) 112, 117, 119, 120, 122 and A 2A AR 125, 131 . Methylated lysines have been used in NMR studies of β 2 AR 116 and the μ-opioid receptor (MOR) 128 . Introduction of NMR probes through chemical modification has been achieved by targeting suitably located endogenous cysteines or lysines, or by replacing amino acids in judiciously selected sequence locations with non-endogenous cysteines 125, 177 . Generally, post-translational chemical modification is limited to residues at the extracellular or intracellular surfaces; however, unintended labelling of non-surface residues can occur, creating unwanted background signals that interfere with the interpretation of NMR data from the surface-facing probes. For example, in A 2A AR, the labelling of a cysteine engineered into the intracellular surface resulted in heterogeneous labelling of additional cysteines when the protein was solubilized in detergent micelles. To overcome this problem, the in-membrane chemical modification (IMCM) method was introduced, whereby 19 F NMR probes are chemically introduced into GPCRs embedded in membranes isolated from the expression host, that is, before protein isolation and purification 177 . Alternatively, 19 F NMR background signals have been removed by replacement of all but the cysteine(s) of interest by other amino acids.
Post-translational chemical modification has also been used to introduce paramagnetic relaxation enhancement (PRE) agents, such as nitroxide spin labels, into discrete sequence locations in proteins [237] [238] [239] . This approach has been widely used in NMR structure determination efforts and in studies of intermolecular interactions of soluble and membrane proteins 237, 240, 241 , using cysteine-modifying chemistry similar to the 19 F NMR approach to introduce such spin labels at discrete locations in GPCRs. 110, 242 . Expression of deuterated GPCRs in eukaryotic organisms has historically been a challenge, as insect and mammalian cells do not tolerate D 2 O, but deuteration of human GPCRs has been achieved by protein production with P. pastoris in D 2 O media 126, 127, 243 . Higher levels of protein deuteration were achieved by adding deuterated carbon sources 126, 243 . Illustrations for successful expression in P. pastoris include deuterated human A 2A AR, enabling of 13 C-methyl labelling of isoleucines 126, 243 245 . Using these approaches, the extent of deuteration may be lower than what is achieved with D 2 O-based expression media for P. pastoris, but back-protonation is expected to be nearly complete 244 . Selective 13 CH 3 labelling of alanine methyl groups on a deuterated background has been achieved for β 2 AR expressed in BVES 246 . Introduction of non-proteinogenic amino acids through amber codon suppression technology has been used to introduce NMR probes into GPCRs for residue-specific biophysical characterization of dynamics and ligand-binding events [247] [248] [249] [250] . Using this approach, 19 F NMR probes such as fluorotyrosine can be introduced at specific interior locations in transmembrane helices that are inaccessible for post-translational chemical modification.
Expression in stable-isotope-labelled media
Expression of human GPCRs in Escherichia coli, which is the standard expression system for stable-isotope-labelled proteins for NMR studies, has so far found limited applications 130, 251, 252 .
Labelling of GPCR ligands and partner proteins
Expression of the isotopically labelled Gα subunit of the trimeric G protein complex has been carried out in E. coli, permitting deuteration and uniform or amino-acid-specific labelling of G proteins 253 . , which are widely distributed in the transmembrane region. Overall, NMR data are now available from observations of probes in strategic locations distributed over the entire 3D molecular structure. In addition, other methods, including fluorescence spectroscopy [147] [148] [149] [150] [151] [152] [153] [154] , electron paramagnetic resonance (EPR) 122 , chemical labelling 155, 156 and hydrogen-deuterium exchange 157 , have been utilized for studying the conformation of β 2 AR. These data have enabled examinations of the global conformational dynamics that determines the efficacies and biased signalling of β 2 AR.
Conformational equilibria related to variations in ligand efficacy have been observed in various regions of β 2 AR, using NMR probes located primarily in positions where large differences were observed between crystal structures of inactive and active-like states 68, 85 . With CF 3 probes at C265
6.27 and C327 7.54 near the cytoplasmic tips of TMVI and TMVII, respectively, equilibria between inactive and active-like conformations were observed, with exchange rates slower than 10 s −1 (REFS 112,120 ), and the population of the active-like state correlated with the ligand efficacy 112 (FIG. 4) . The exchange rates observed using a single-molecule fluorescence probe at C265 6.27 were similar to those observed using the CF 3 probe 152 . Additionally, faster intramolecular rate processes were discovered by observation of the M82 side chain, which reflects the conformation of the P/I/F motif in the central transmembrane region 113 . Equilibria among two conformations containing the inactive P/I/F motif, PIFoff 1 and PIFoff 2 , and one conformation with the active P/I/F motif, PIFon, were observed (FIG. 3) , and the population of the latter correlated with different ligand efficacies 113 . Remarkably, the exchange rates seen for the P/I/F motif were larger than those observed for the CF 3 probe at C265 6.27 , that is, ~2,000 s −1 . This exchange rate is in closer agreement with k ex >100 s −1 , observed using single-molecule spectroscopy with fluorescence resonance energy transfer (FRET) probes at positions N148C 4.40 and L266C 6.28 . FRET is sensitive to variations of the TMIV-TMVI distance in the interior region, which thus appears to also reflect the conformation of the P/I/F motif. In the case of M215 5.54 , for which the chemical shifts of the peripheral 13 CH 3 group reflect both the activation state of the P/I/F motif and the in FIG. 3b , where the exchange rates of the P/I/F motif activation are different from those of the conformational exchange near the intracellular surface, as manifested by the 19 F probe at C265 6.27 . CPMG experiments with another CF 3 probe, BTFMA, at C265 of β 2 AR in the apo and inverse agonist-bound states indicated that C265 underwent conformational rate processes with exchange rates >1,000 s −1 (REFS 122, 146 ), suggesting that in the inactive state, the cytoplasmic surface region of β 2 AR is characterized as a manifold of rapidly exchanging substates.
NMR studies of β 2 AR provided a structural basis for the biased signalling of GPCRs 112 . Carvedilol and isoetharine share similar chemical structures with the inverse agonist carazolol and the full agonist isoprenaline, respectively, and have been classified as β-arrestin-biased ligands of β-adrenergic receptors 158, 159 . Arrestin signalling through β 2 AR promotes cardiomyocyte survival, and the arrestin-biased β 2 AR ligands represent a potentially useful therapeutic approach 160 . Liu and colleagues 112 observed the resonances of 19 F labels introduced at C265
6.27 and C327 7.54 , which are at the cytoplasmic ends of TMVI and TMVII of β 2 AR, respectively, and demonstrated that β-arrestin-biased ligands predominantly affected the conformation of C327 7.54 (FIG. 4a,b) . These results suggested that β-arrestin-biased ligands of β 2 AR induce conformational changes of TMIII and TMVII, where the populations of inactive and active-like states seen in this location are not paralleled by those seen at C265 6.27 for TMV and TMVI (FIG. 4c) . Experiments with β-adrenergic receptors have also provided useful lessons for improving the technologies for, and the interpretation of, structural studies of GPCRs (BOX 3, FIG. 5 ).
μ-Opioid receptor. This class A GPCR is stimulated by various opioid drugs, including morphine. Studies have indicated that MOR signalling through G i (the inhibitory G protein for adenylyl cyclase) plays a key role in the desired analgesic properties of morphine, whereas signalling through β-arrestin is associated with adverse effects such as respiratory depression 161, 162 . This knowledge has led to efforts to identify biased MOR ligands that show enhanced G i signalling and reduced β-arrestin signalling compared with morphine, including oliceridine (TRV130) 163 , PZM21 (REF.
57
) and SR17018 (REFS 55, 56 ), which result in increased analgesia with reduced on-target adverse effects 52, 53, 57 . Further understanding of the mechanisms underlying biased MOR signalling is therefore of high interest for the development of much-needed novel analgesics.
Crystal structures of MOR have been solved in various forms, including those bound to inverse agonists and to a full agonist with a G protein-mimicking nanobody 164, 165 . Activation-induced conformational changes of the structural motifs that are widely conserved among
Box 2 | Reconstitution of human GPCRs for NMR studies in solution
Under physiological conditions, G protein-coupled receptors (GPCRs) are embedded in lipid bilayers, whereas for structural studies, they have so far in most cases been solubilized by detergents. In detergent micelles, GPCRs do not necessarily retain their full activities 255 , and a lipid bilayer environment is reportedly preferable for GPCR phosphorylation by GPCR kinases 256 . Nanodiscs can accommodate membrane proteins within a 10 nm-diameter disc-shaped lipid bilayer, stabilized by α-helical amphipathic membrane scaffold proteins (MSPs) 257, 258 . Nanodiscs thus promise to provide a lipid environment with more native-like properties in terms of the lateral pressure and curvature profiles, as detergent micelles have a strong curvature and different lateral pressure profiles from lipid membranes 259 . Membrane proteins embedded in nanodiscs are attractive for investigating interacting ligands on one side and signalling partner proteins on the other side. Nanodiscs are water soluble and monodisperse, which have enabled their use in various GPCR studies 121, 124, 130, 151, 152, 203, 204, 255, [260] [261] [262] [263] [264] [265] [266] [267] [268] . Nasr et al. 269 recently reported covalently circularized nanodiscs (cNDs) with enhanced stability and strictly defined diameters, which were obtained by circularizing the MSP using sortase . The NMR spectra of a β-barrel membrane protein, VDAC1, embedded in cNDs exhibited enhanced signal intensities and spectral resolution owing to reduced sample heterogeneity 269 , suggesting that cNDs could facilitate future NMR analyses of GPCRs in lipid bilayers. Disc-shaped lipid bilayers have also been formed using the saposin A scaffold protein (Salipro nanoparticles 270, 271 ) or synthetic polymers 217, 272 . Saposin A scaffold proteins are reportedly helpful for the formation of bilayer discs with different sizes, and the synthetic polymer discs have the advantage of being formed directly from lipid bilayers, without the use of detergents.
Under physiological conditions, GPCRs can be embedded in the lipid bilayers of tissues with various lipid compositions, and the signalling activities of GPCRs can be affected by the lipid composition of the bilayers. For example, experimental studies using the β 2 -adrenergic receptor (β 2 AR) in nanodiscs indicated that phospholipids can act as allosteric modulators 255 , and the NMR signals of the leukotriene B 4 receptor in nanodiscs were found to be affected by the addition of cholesteryl hemisuccinate 130 . Reconstitution of GPCRs into nanodisc lipid bilayers thus opens avenues to examine the effects of various compositions of lipid bilayers on the activities and conformational equilibria of GPCRs by solution NMR experiments at near-physiological temperatures. class A GPCRs, including the cytoplasmic cavity formation, were also observed for the MOR structures. These crystal structures were complemented in important ways by NMR studies. Sounier 6.36 of MOR, which are sensitive to conformational changes of TMIII, TMV, TMVI and TMVII, in the balanced and biased ligand-bound states. The chemical shifts of these residues correlated well with the bias factors, which are the ratios of the β-arrestin signalling efficacies to the G protein signalling efficacies in each state (FIG. 6a) . These results, along with temperature-dependent shifts of these resonances, suggested that the intra cellular cavity of MOR exists in an equilibrium between a closed and multiple open conformations, with coupled rearrangements of the transmembrane helices III, V, VI and VII, and that the relative populations of the open conformations determine the G protein-mediated and arrestin-mediated signalling levels in different ligand-bound states (FIG. 6b) .
A 2A adenosine receptor. The A 2A adenosine receptor (A 2A AR) plays myriad roles in human health, including regulating myocardial blood flow, and it is heavily expressed in the central nervous system, where it is involved with dopamine and glutamine release 166, 167 . A 2A AR has recently also become a promising target for developing cancer immunotherapies [168] [169] [170] [171] [172] . To this end, the 19 F NMR signals of CF 3 groups introduced at the cytoplasmic ends of transmembrane helices TMVI and TMVII were compared for β 2 AR with and without T4 lysozyme fused into intracellular loop 3 (ICL3). The fusion of T4 lysozyme into the ICL3 was thus found to block the conformational equilibrium seen at the cytoplasmic tip of TMVI in the active-like state, independent of the ligand bound to β 2 AR 123 (FIG. 5a) . In addition, in the apo and noradrenaline-bound states, the fusion of T4 lysozyme induced a long-range effect via the orthosteric cavity on the conformational equilibrium at the cytoplasmic tip of TMVII 123 (FIG. 5a) . The observation at C265 is in apparent contrast with data from earlier fluorescence experiments with β 2 AR-T4 lysozyme 67 , which measured the overall effect of the fusion protein on labels in positions 265 and 327. By contrast, by individually labelling C265 and C327 in the 19 F NMR study, the separate response at each of the cytoplasmic ends of TMVI and TMVII could be measured. The NMR results now provide a rationale for the fact that the fluorescence experiments, which were designed before the crystal structure was known, did not reveal the status of TMVI, because the changes in the fluorescence measurements between agonist and antagonist complexes were dominated by the probe at C327 (REF.
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). The results obtained by measurements in solution emphasize that the effects of ICL3 fusions and/or thermostabilizing mutations on the conformational equilibria in GPCRs should be duly considered in functional interpretations of GPCR crystal structures obtained with such protein modifications.
NMR views of the impact of thermostabilizing amino acid substitutions on GPCRs
A thermostabilized variant of the β 1 -adrenergic receptor (β 1 AR), which has 56% sequence identity to β 2 AR, was prepared with (FIG. 5b) , which reflects the previously mentioned fact that the thermostabilization used locks the receptor in the inactive conformation, as confirmed by X-ray crystallography 92 . Nonetheless, NMR spectroscopy revealed subtle differences in line shapes and chemical shifts (FIG. 5b) , which were used to obtain novel insights. For example, chemical shift changes upon formation of a ternary complex with the G protein-mimicking nanobody Nb80 were reported for valines located throughout the receptor, representing 'reverse' allosteric effects near the extracellular surface from complex formation with the nanobody at the intracellular signalling surface 114 . Allosteric effects of β 1 AR complex formation with G protein-mimicking nanobodies were also observed with the use of 13 C-methyl-methionine labels 115 .
NMR views of the impact of different membrane mimics on GPCRs
Comparative NMR studies of a β 2 AR complex with a partial agonist in nanodiscs and in dodecyl maltoside (DDM) micelles revealed that the exchange rates between the conformations with inactive and active P/I/F motifs are lower in nanodiscs than in detergent micelles (BOX 2) and that the population of the conformation with an active P/I/F motif of β 2 AR is higher in nanodiscs than in DDM micelles 121 (FIG. 5c) . NMR analyses of other membrane proteins embedded in nanodiscs also showed modulation of the conformational equilibria and the functions of membrane proteins by the lipid bilayer environment 108, 273 . The maximum cAMP response, calculated using the populations of the conformations with the active P/I/F motif of β 2 AR in nanodiscs, correlated better with the experimental values than those calculated for β 2 AR in DDM micelles 121 (FIG. 5d) . These NMR investigations of GPCRs, along with work with other membrane proteins, indicate that data on membrane proteins in detergent micelles need to be carefully evaluated, as different values were measured for the relative populations of the different conformational states and the exchange rates between them in the lipid bilayer environment of nanodiscs. 
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agonist and a 'mini' G protein 176 . For NMR spectroscopy, it is of interest that A 2A AR has been expressed in multiple cell types, including Pichia pastoris, insect cells and mammalian cells, permitting many options for stable-isotope labelling
19
F-NMR has been used to study A 2A AR by post-translational chemical modification of non-endogenous cysteines introduced at positions near the intracellular surface, which were labelled with 19 F-BTFMA 125 , or by in-membrane chemical modification with TET 177, 178 , and then studied in detergent micelles. One-dimensional 19 F-NMR spectra were measured for A 2A AR complexes with ligands of different efficacies. Efficacy-dependent changes of the relative populations of different conformational states were observed 125, 178 , which were also shown to respond to variable salt concentrations 131 .
[u-15 N, ~70% 2 H]-human A 2A AR was expressed in P. pastoris, and single amino acid replacements were used for the assignment of all six tryptophan indole 15 (FIG. 7a) . The distribution of NMR probes (FIG. 7b) permitted a global view of the response of the A 2A AR structure and dynamics to the variable efficacy of bound drugs. Effects of the inactivation of an allosteric centre by replacement of residue Asp52 2.50 with Asn resulted in local changes in the orientation of the toggle switch Trp246 6.48 relative to the P/I/F activation motif (FIG. 7c,d ), which are directly correlated with both a change of conformational dynamics at the intracellular surface and loss of G protein signalling 127 (FIG. 7e) . 3.40 and I292 8.47 were assigned by amino acid replacement 126 . NMR experiments for A 2A AR complexes with ligands of different efficacies indicated that inverse agonists suppressed high-frequency motions on the intracellular signalling surface, and large conformational changes were observed depending on the sodium concentration in the A 2A AR solutions 126 . A 2A AR has an exceptionally long C-terminal polypeptide 'tail' compared with class A GPCRs in general, that is, 122 residues rather than 30-40 residues. In crystallization constructs, the A 2A AR amino acid sequence was truncated at position 316 in order to facilitate crystallization. NMR studies of the isolated C-terminal polypeptide showed that it is intrinsically disordered 179, 180 , and additional biophysical data suggested that this intrinsic flexibility is important for complex formation with various partner proteins, including calmodulin 179 . Intrinsically disordered polypeptide segments in GPCRs have been shown to be subject to post-translational modifications and are thought to be critical for interactions with G proteins and other partner proteins 181 . NMR is especially well suited for studying intrinsically disordered polypeptides 182, 183 . Class B GPCRs. Class B GPCRs are composed of a 100-150-residue N-terminal extracellular domain (NTD or ECD) and a canonical transmembrane domain with seven transmembrane α-helices. This class comprises 15 receptors, which all bind polypeptide hormones 30, 31 . Class B GPCRs are involved in key physiological processes and associated diseases, including diabetes, osteoporosis, cancer, neurodegeneration, cardiovascular disease, migraine and psychiatric disorders 31 , and thus are attractive drug targets 184 . Examples include numerous GLP1R agonists that are in use for the treatment of diabetes; the peptide tesamorelin, a growth hormonereleasing hormone receptor (GHRHR) agonist; and teduglutide, a GLP2R agonist 4, 185 . However, no smallmolecule agonist drugs directed at class B receptors have been approved so far, and thus, new structural information about class B GPCRs is expected to open exciting new perspectives 4 . For NMR applications, it is of interest that various class B GPCRs have been reported to exhibit biased signalling and allosteric modulation, 
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) (see also FIG. 4) . The transmembrane helices TMI to TMV are shaded in grey. TMVII, which is in equilibrium between two conformational states manifested by different NMR chemical shifts of a 19 F probe attached to C327, is represented as dashed cyan rectangles. TMVI, which is blocked in an active-like state by T4L fusion, is represented by solid blue outlined rectangles. The T4L fusion protein is depicted as a small red oval, the direction of its impact on local conformational equilibria is indicated by grey arrows and the increased intensity of its impact is indicated by increased density of the red shading. The positions of the 19 F NMR labels are shown by yellow spheres, where the active-like state is further identified by a black circle. The orthosteric ligand-binding cavity is indicated by shading. The upper panel represents the ligand-binding cavity in the complex with the small ligand noradrenaline (small green rectangle; in the apo form, the cavity does not contain a ligand); the grey arrows indicate that a long-range effect from T4L via the orthosteric ligand-binding cavity causes a shift in the conformational equilibrium at the intracellular tip of TMVII. The lower panel shows the orthosteric binding site containing one of the listed larger ligands (green rectangle); the long-range effect from T4L to TMVII is suppressed by the presence of these ligands, which carry a hydrophobic substituent at the ethanolamine end. b | [ . Differences to class A GPCRs arise because the residues that exhibit the largest conformational changes upon activation in class A GPCRs, such as the P/I/F, NPxxY and D(E)RY motifs 60 , are not conserved in class B GPCRs 31 and, furthermore, the extracellular N-terminal domain of class B GPCRs may also be directly involved in the regulation of signalling. Overall, the extensive knowledge of class A GPCR structures is thus not directly applicable to class B GPCRs.
Class B GPCRs offer new possibilities for applying NMR to study mechanisms of ligand recognition and intracellular signalling. Most endogenous class B GPCR ligands are polypeptides, which can be labelled with stable isotopes 186 to study their detailed atomic interactions with receptors by NMR. The possibility also arises to use NMR in parallel with intein chemistry to selectively label different segments of the GPCR sequence with 2 , and the equilibrium within the active substates is shifted towards the conformation preferred for G protein activation. In the DAMGO-bound state of the MOR N152 3.35 A mutant, where MOR adopts only the active conformation, the equilibrium among the active substates is shifted towards the conformation preferred for arrestin activation. Parts a and b are adapted with permission from REF.
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, Wiley-VCH.
domains within the full-length receptor would be an obvious extension of this work. NMR can thus provide information by observation of the endogenous ligand, the GPCR, intracellular partner proteins or combinations thereof, as all these components can be individually labelled with NMR-observable probes that provide direct experimental access to ligand and partner protein binding mechanisms that underlie the physiological signalling by class B GPCRs.
NMR in GPCR drug discovery
The above sections summarize how NMR studies on GPCRs have complemented structural understanding from other biophysical techniques and highlighted opportunities for drug discovery. Here, we discuss the two main ways in which NMR studies can be used in pursuing such opportunities: applications in fragment-based screening to identify starting points for drug discovery, and understanding and optimizing the pharmacological characteristics of GPCR-targeted drugs.
NMR support of fragment-based lead discovery. Fragment-based screening (FBS) uses libraries of thousands of small molecular fragments to find starting points for developing novel drugs. This contrasts with high-throughput screening (HTS) of millions of compounds to find drug-sized starting compounds. Sampling of the chemical space tends to be more efficient with molecular fragments than with larger molecules, and as they form fewer interactions, small fragments bind to a wider range of sites on a greater number of proteins, leading to higher hit rates 187 . However, the binding affinities of small molecular fragments are likely to be lower than those for larger molecules and, therefore, high assay sensitivity is needed in FBS. NMR spectroscopy was the first method used successfully to screen fragments 188 , and it is still a commonly used method 17 . FBS has been applied to GPCRs with thermostabilization 189 , and NMR has been utilized for FBS targeting β 1 AR 190 and A 2A AR 191, 192 . Ligandobserved NMR methods, such as target-immobilized NMR screening (TINS) and saturation transfer difference spectroscopy (STD) (FIG. 8a,b) , have been utilized for FBS with β 1 AR 190 and A 2A AR 191, 192 ; fragments have been identified that inhibited binding of tritium-labelled ligands with half-maximal inhibitory concentration (IC 50 ) values ranging from 5 μM to 5 mM. Special advantages of these methods include the detection of weak binders, the requirement of less protein than protein-observed NMR experiments, the lack of requirement for isotope labels and the lack of an upper size limit for the protein 187, 193 . The main challenge in FBS is in lead optimization, where structural information is required to decide on where to grow, merge or link a given fragment 194 . NMR methods can provide such information. Using forbidden coherence transfer (FCT) measurements 195 , which are sensitive to the degree of surface complementarity, the substitution position at which to grow the ligands can be identified. Transferred nuclear Overhauser effect (NOE) spectroscopy 132, 196, 197 (FIG. 8c) and interligand NOEs for pharmacophore mapping (INPHARMA) 135, 198 (FIG. 8d) provide information on how to merge or link fragments in lead optimization processes. STD NMR [199] [200] [201] has also been applied for epitope mapping and determination of the bound conformations of GPCR ligands [202] [203] [204] [205] . The bound conformations of ligands for the κ-opioid receptor, pituitary adenylyl cyclase-activating polypeptide receptor and leukotriene receptor BLT2 have been determined by transferred NOE spectroscopy 132, 197, 205 , and INPHARMA has been applied for the generation of docking models of A 2A AR and GPR40 (REFS 135, 198 ).
NMR for optimization of drug pharmacological characteristics. An attractive goal for structure-based drug design is to improve the specificity of receptor-ligand interactions while increasing ligand affinities, efficacies and desired biased signalling. It has been proposed that structures of mutant GPCRs with increased thermostability in the agonist-bound state can be utilized for the development of agonists 4 , and biased ligands of opioid receptors were identified by a structure-based approach 57, 206 , using inactive crystal structures in the antagonist-bound state. In this respect, NMR can provide structural information about conformational equilibria that are related to both the ligand efficacies and biased signalling in GPCRs. In addition, NMR studies revealed relationships between the chemical structures of GPCR ligands and their biased signalling, indicating that NMR studies would be helpful for the design of biased ligands.
For example, conformational changes of TMIII and TMVII in β 2 AR that are not paralleled by those of TMV and TMVI in complexes with β-arrestin-biased ligands are in agreement with the following structure-activity relationships of β 2 AR ligands (FIG. 9a,b) . Modifications of the ethanolamine tail moieties, which are bound to TMIII and TMVII in the crystal structures 68, 81, 207 , result in selective modulation of the efficacies for β-arrestin signalling, whereas modifications of the aromatic head groups, which bind to TMV and TMVI in the crystal structures 81, 85, 207 , affect the efficacies of both G proteinmediated signalling and β-arrestin-mediated signalling 112 . Results from crystallography of the serotonin 5-HT 1B and 5-HT 2B receptors bound to ergotamine 208 and from fluorescence studies of the ghrelin receptor GHS-R1a 209 and the arginine vasopressin type 2 receptor 154 are also in agreement with selective activation of G protein-mediated and β-arrestin-mediated signalling by localized conformational changes of TMV and TMVI and of TMIII and TMVII, respectively.
For MOR, a comparison of oliceridine derivatives, composed of the 2-[6-oxaspiro[4.5]decan-9-yl]ethylamine scaffold and two aromatic groups attached to the oxaspiro [4, 5] decan and ethanolamine moieties (FIG. 9c) , including compounds 6-11 and 13-19, revealed that the modification of either of the two aromatic rings results in the selective modulation of β-arrestin signalling 163 . These structure-activity relationships of the oliceridine derivatives are in agreement with a population shift of the conformational equilibria that accompanies the global conformational changes in TMIII, TMV, TMVI and TMVII upon the β-arrestin-biased N152A as revealed by NMR 129 (FIG. 9d) . The coupled conformational changes of TMIII, TMV, TMVI and TMVII are also in agreement with the structure-activity relationships of the D 2 dopamine receptor: the modification of both the head and tail groups of the ligands for the D 2 dopamine receptor resulted in the selective modulation of β-arrestin signalling 210 . The mobility of the ECLs of GPCRs can affect the binding kinetics of ligands that attach to the binding pocket, and the binding kinetics correlate with the duration of drug action 78 . In molecular dynamics simu lations of M 2 and M 3 muscarinic acetylcholine receptors bound to the ligand tiotropium, the ECL2 of the M 3 receptor bound to tiotropium exhibited lower mobility than that of the M 2 receptor 211 . The reduced mobility of the M 3 receptor appears to parallel the slow association and dissociation of the ligand, and slow dissociation from the M 3 receptor is responsible for the clinically preferable long-acting profile of tiotropium. In addition, ligands may adopt multiple different binding modes to their target molecules 212 , and heterobivalent or nonbivalent ligands that are able to bind in two different orientations to the GPCRs have been identified for MOR, the muscarinic M 2 receptor, the histamine H 1 receptor and the dopamine D 3 receptor 213, 214 . In the case of the bipharmacophoric ligands of the muscarinic M 2 receptor 214 , consisting of an active moiety and an inactive moiety, the ligand-binding modes dynamically switch between an active signalling-competent pose and an inactive binding pose. The population of the active pose is related to the efficacies and is affected by the affinity ratio between the active and inactive moieties 214 . We conclude that dynamic ligand binding in multiple binding modes is a novel and promising feature to be considered for the rational design of agonists with predictable efficacies.
Finally, NMR has been utilized for investigations of the conformational equilibria in the ligand-binding sites of GPCRs
132
, which are important for structure-guided drug design 215 . In an NMR study of the κ-opioid receptor and its peptide ligand, motion on the sub-nanosecond timescale was observed for the N-terminal region of the ligand, which is known to be crucial for activation 132 . Sub-nanosecond timescale motion in the ligand-binding site is correlated to the surface complementarity 195, 216 ; observation and optimization of ligand mobility thus promise to provide important input for the design of ligands with improved affinities.
Outlook
Since 2007, X-ray crystallography has set high standards for structure determination of human GPCR complexes with a wide range of drug molecules and other ligands, and the potential of cryo-EM to provide structure determinations of higher-order complexes of GPCRs with ligands, modulators and partner proteins is now rapidly developing. While this Review primarily discusses the integrative use of X-ray crystal structures and NMR spectroscopy in solution, the inclusion of cryo-EM results is an exciting prospect, which may dominate the field in the future. Compared with X-ray crystallography, cryo-EM has much higher potential to provide structures of multiple simultaneously populated conformations in a given sample preparation 32 . It is exciting to look forward to combining this information on static arrays of different structures with the potential of solution NMR to characterize local and global three-dimensional structures in GPCRs and to provide information on the relative populations of the different macromolecular species and the exchange kinetics among them.
In this Review, we have emphasized the ability of NMR to study wild-type or near-wild-type GPCRs in aqueous media at physiological temperatures. In the future, it will be important to further enable studies of GPCRs in sample preparations that also represent close mimics of other aspects of the physiological environment. In this context, the development of specialized, sophisticated GPCR biochemistry is warranted. This may include the formation of lipid bilayer discs directly from cell membranes 217 or the preparation of size-controlled liposomes using a DNA nanotemplate 218 , enabling NMR spectroscopy with GPCRs reconstituted in lipid mixtures that closely mimic those found in living cells. Combined with these improvements in GPCR reconstitution
, refined stable-isotope labelling (BOX 1) will be needed, such as the use of non-native amino acids to introduce NMR probes at discrete locations in GPCRs expressed in mammalian or insect cells and the use of segmental labelling for NMR studies of selected polypeptide segments in intact GPCRs 124 . However, refined GPCR biochemistry for NMR may come at the cost of , the so-called 'toggle switch' tryptophan 275, 276 , is highly responsive to variable drug efficacy, as observed by comparing NMR spectra for A 2A 5.61 and M283 6.36 are shown as purple spheres. NMR studies observing 13 CH 3 groups of these four methionines suggest that TMIII, TMV, TMVI and TMVII are involved in G protein or arrestin signalling bias. Part c is adapted with permission from REF.
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lower expression and purification yields, and thus the success of new approaches will also require advances in NMR technologies. Dynamic nuclear polarization NMR, which can provide orders-of-magnitude increases in experimental sensitivity for studies of challenging systems, appears particularly promising 219, 220 and is already extensively used in solid-state NMR 136, [221] [222] [223] [224] . Overall, there is the promise that NMR studies in solution environments that are ever closer to the physiol ogical milieu will be used to investigate the structural basis of the impacts of cellular traits on GPCR function 12 . Specifically, this will address phenomena such as GPCR oligomerization 225, 226 , post-translational modifications 227 and complex formation with other partners such as receptor activity-modifying proteins 228 . Awaiting these technical advances and an abundance of new data from cryo-EM, we look forward to exciting times for the use of solution NMR in integrative GPCR structural biology projects. Each step forward in structural biology will support the discovery of new drugs, as well as the improvement of existing drugs and their application.
